11th Annual USC Multi-Disciplinary Breast Cancer Symposium

Add to Calendar 11th Annual USC Multi-Disciplinary Breast Cancer Symposium 1/27/2024 7:55:00 AM 1/27/2024 4:35:00 PM America/Los_Angeles For More Details: https://keckusc.cloud-cme.com/breastcancer2024 Description: This program will review the current state-of-the-art for breast cancer management, highlighting the key components of multi-disciplinary treatment to include breast imaging, oncofertility, breast pathology, surgical oncology, reconstructive microsurgery, medical oncology, and radiation oncology. The format of this program will consist of lectures by international experts in their fields.Over the past year, advance... SLS Hotel false MM/DD/YYYY


Date & Location
Saturday, January 27, 2024, 7:55 AM - 4:35 PM, SLS Hotel

Credits
AMA PRA Category 1 Credits™ (7.25 hours), Non-Physician Attendance (7.25 hours)

Overview
This program will review the current state-of-the-art for breast cancer management, highlighting the key components of multi-disciplinary treatment to include breast imaging, oncofertility, breast pathology, surgical oncology, reconstructive microsurgery, medical oncology, and radiation oncology. The format of this program will consist of lectures by international experts in their fields.
Over the past year, advances in clinical trials have demonstrated the utility of antibody-drug conjugates, immunotherapy, genomic assays in hormone receptor-positive breast cancer, and downstaging surgical management of the axilla. The evolution of reconstructive microsurgery in oncoplastic and lymphedema surgery proceeds at a rapid pace. These developments, along with data on resistance to endocrine therapy and therapy targeting the HER2 axis, make individualized management decisions increasingly important in treating patients with breast cancer. Newer radiation therapy treatment strategies and clinical trials in radiation oncology continue to evolve.  Evolving technology in breast imaging, specifically tomosynthesis, is challenging conventional imaging techniques. Breast cancer in young women has become a specialized field in oncology, which is seeing increasing visibility. Inflammatory cancer continues to be a challenging area where new therapeutic concepts are emerging. These breakthroughs allow personalized breast cancer treatments to maximize benefits and minimize treatment toxicities.
The understanding of the HER2 receptor continues to evolve. Key talks in medical oncology will focus on HER2+ breast cancer therapeutics in the metastatic setting, the use of newer agents in metastatic ER+ cancers, and the evolution of immunotherapy as a central theme in the treatment of triple-negative breast cancer.

Objectives

By the end of the course, participants will be able to: 


  1. Assess decision-making process in surgical management of the axilla, including the use of axillary ultrasound to re-stage the axilla after neoadjuvant chemotherapy.
  2. Summarize use of genomic assays for patients who are candidates for ovarian function suppression, including the OFSET CHEMO trial.
  3. Explain the importance of fertility preservation during breast cancer treatment.
  4. Classify evolving concepts in treatment of HER2-low breast cancer.
  5. Explain the biology of the HER2 axis and its role in treating metastatic cancer.
  6. Define the role of CDK inhibitors in treating metastatic and resistant ER+ cancers.
  7. Incorporate the evolving role of clinical trials in radiation therapy.
  8. Assess the impact of advances in breast imaging using PET scanning aimed at the estrogen receptor (FES-PET).
  9. Appreciate the evolution of antibody drug conjugates as a treatment strategy for advanced breast cancer.

Accreditation
The Keck School of Medicine of the University of Southern California is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Keck School of Medicine of the University of Southern California designates this activity for a maximum of 7.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 


Additional Information

Cancellation Policy

Cancellations must be received by the USC Office of CME by email only by January 23, 2024 at 12:00 pm PDT for a refund. A $50 cancellation fee will be applied. In the event of course cancellation by conference organizers, all registration fees will be fully refunded. USC will not refund any travel costs incurred.


Accessibility Statement
 
Keck School of Medicine Healthcare System is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008. If you have needs that require special accommodations, including dietary concerns, please contact the USC Office of CME at [email protected].